Paul G Rubinstein
Overview
Explore the profile of Paul G Rubinstein including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
394
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Cesarman E, Chadburn A, Rubinstein P
Blood
. 2021 Sep;
139(7):1013-1025.
PMID: 34479367
Kaposi sarcoma (KS) herpesvirus (KSHV), also known as human herpesvirus 8, is the causal agent of KS but is also pathogenetically related to several lymphoproliferative disorders, including primary effusion lymphoma...
12.
Ramos J, Sparano J, Chadburn A, Reid E, Ambinder R, Siegel E, et al.
Blood
. 2020 May;
136(11):1284-1297.
PMID: 32430507
EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin) is a preferred regimen for HIV-non-Hodgkin lymphomas (HIV-NHLs), which are frequently Epstein-Barr virus (EBV) positive or human herpesvirus type-8 (HHV-8) positive. The histone...
13.
Rubinstein P, Moore P, Rudek M, Henry D, Ramos J, Ratner L, et al.
AIDS
. 2017 Dec;
32(5):605-611.
PMID: 29280762
Objective: Brentuximab vedotin is a Food and Drug Administration approved anti-CD30 antibody drug conjugate potently active in Hodgkin lymphoma. Trials of brentuximab vedotin with doxorubicin, vinblastine, and dacarbazine (AVD-BV) excluded...
14.
Gupta N, Nolan A, Omuro A, Reid E, Wang C, Mannis G, et al.
Neuro Oncol
. 2016 Sep;
19(1):99-108.
PMID: 27576871
Background: The optimal therapeutic approach for patients with AIDS-related primary central nervous system lymphoma (AR-PCNSL) remains undefined. While its incidence declined substantially with combination antiretroviral therapy (cART), AR-PCNSL remains a...
15.
Kowalczyk M, Rubinstein P, Aboulafia D
J Int Assoc Provid AIDS Care
. 2014 Dec;
14(3):211-6.
PMID: 25504472
HIV-associated immune thrombocytopenic purpura (ITP) has decreased in incidence 10-fold since the advent of highly active antiretroviral therapy (HAART). For patients with detectable HIV viral loads, first-line treatment approaches involve...
16.
Reichel J, Chadburn A, Rubinstein P, Giulino-Roth L, Tam W, Liu Y, et al.
Blood
. 2014 Dec;
125(7):1061-72.
PMID: 25488972
Classical Hodgkin lymphoma (cHL) is characterized by sparsely distributed Hodgkin and Reed-Sternberg (HRS) cells amid reactive host background, complicating the acquisition of neoplastic DNA without extensive background contamination. We overcame...
17.
Rubinstein P, Aboulafia D, Zloza A
AIDS
. 2014 Jan;
28(4):453-65.
PMID: 24401642
The incidence of AIDS-defining cancers (ADCs) - Kaposi sarcoma, primary central nervous system lymphoma, non-Hodgkin lymphoma, and cervical cancer - although on the decline since shortly after the introduction of...
18.
Hodowanec A, Han A, Barker D, Rubinstein P, Max B
J Int Assoc Physicians AIDS Care (Chic)
. 2012 Aug;
11(6):345-7.
PMID: 22930795
Venous thrombosis is a well-described complication of thalidomide therapy in patients with multiple myeloma (MM). However, an association between thalidomide use and thrombosis in HIV-positive patients has not been previously...
19.
Rubinstein P, Lindgren V, Setty S, Yao M, Pytynia K, Radosevich J, et al.
J Clin Oncol
. 2010 Dec;
29(9):e222-5.
PMID: 21189379
No abstract available.
20.